IP Library Granted Patent US 11,612,622
Granted Patent B2
US 11,612,622 · App. 16/219,125 · Granted Mar 28, 2023

Probiotic compositions containing clostridiales for inhibiting inflammation

Inventors: David Berry (Waban, MA); Johanne Kaplan (Sherborn, MA); Shaila Rahman (Cambridge, MA)
Assignee: Evelo Biosciences, Inc.
A61K35/74A61K9/0031A61K9/0053A61K9/19A61K31/7004A61K31/7016A61K31/715A61K35/39A61K35/741A61K35/742A61K35/744A61K35/745A61K35/747A61K38/46A61P29/00A61P37/00A61P43/00A61K2035/115Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,612,622
App. No.
16/219,125
Granted
Mar 28, 2023
Kind
B2
Abstract

Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Claims (9)

1. A method of treating autoimmune or inflammatory disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a bacterial population of a single bacterial species, wherein the single bacterial species is Blautia hydrogenotrophica , such that inflammation in the subject is reduced.

2. The method of claim 1 , wherein administering the pharmaceutical composition to the subject reduces secretion of at least one pro-inflammatory cytokine by immune cells of the subject.

3. The method of claim 2 , wherein the pro-inflammatory cytokine is selected from the group consisting of IL-1a, IL-6, IFNγ and TNF alpha.

4. The method of claim 2 , wherein the immune cells are peripheral blood mononuclear cells (PBMCs).

5. The method of claim 1 , wherein administering the pharmaceutical composition to the subject increases secretion of at least one anti-inflammatory cytokine by immune cells of the subject.

6. The method of claim 5 , wherein the anti-inflammatory cytokine is selected from the group consisting of IL-4, IL-5, IL-9, IL-10 and IL-13.

7. The method of claim 5 , wherein the immune cells are peripheral blood mononuclear cells (PBMCs).

8. The method of claim 1 , wherein administering the pharmaceutical composition to the subject increases the proportion of regulatory T cells in the subject.

9. The method of claim 1 , wherein the autoimmune or inflammatory disease is selected from the group consisting of inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, multiple sclerosis (MS), systemic lupus erythematosus (SLE), type I diabetes, rheumatoid arthritis (RA), Sjögren's syndrome, uveitis, and Celiac disease.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 16, 2024
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: EVELO BIOSCIENCES, INC.
Reel/Frame 067118/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2024
From: EVELO BIOSCIENCES, INC.
To: PHARMABIOME AG
Reel/Frame 067120/0665 →
SECURITY INTEREST Recorded Jul 14, 2023
From: EVELO BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064274/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: KAPLAN, JOHANNE
To: EPIVA BIOSCIENCES, INC.
Reel/Frame 048997/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: BERRY, DAVID
To: FLAGSHIP VENTURES MANAGEMENT, INC.
Reel/Frame 048997/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: FLAGSHIP VENTURES MANAGEMENT, INC.
To: EVELO BIOSCIENCES, INC.
Reel/Frame 048997/0198 →
MERGER Recorded Apr 25, 2019
From: EPIVA BIOSCIENCES, INC.
To: EVELO BIOSCIENCES, INC.
Reel/Frame 048997/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: RAHMAN, SHAILA
To: FLAGSHIP PIONEERING, INC. (F/K/A FLAGSHIP VENTURES MANAGEMENT, INC.)
Reel/Frame 048996/0970 →
Continuity (11)
Continuation 15438271 · Feb 21, 2017
Continuation 14952895 · Nov 25, 2015
Provisional Application 62257714 · Nov 19, 2015
Provisional Application 62162562 · May 15, 2015
Provisional Application 62117639 · Feb 18, 2015
Provisional Application 62117632 · Feb 18, 2015
Provisional Application 62117637 · Feb 18, 2015
Provisional Application 62084536 · Nov 25, 2014
Provisional Application 62084540 · Nov 25, 2014
Provisional Application 62084537 · Nov 25, 2014
Related Publication 20190336543A1 · Nov 7, 2019